Transplant Registry Unified Management Program
Biotech Industry Prepares for Trump 2.0: Regulatory Changes and M&A Activity Expected
Biotech industry, Trump 2.0, FDA changes, M&A activity, regulatory environment, pharmaceutical industry, healthcare policy
Trump’s Re-Election: A Mixed Bag for Biopharma with M&A Upsides and Vaccine Concerns
Trump Administration, Biopharma, Mergers and Acquisitions, Vaccine Policy, Robert F. Kennedy Jr., FDA Independence, Inflation Reduction Act
Controversial Stanford Professor Jay Bhattacharya Nominated by Trump to Lead NIH Amid Criticism Over Pandemic Views
Jay Bhattacharya, NIH Director Nomination, COVID-19 Pandemic Response Critic, Stanford University Professor, Trump Administration, Public Health Research, Controversial Appointment
Trump’s NIH Leadership Plans: From Jay Bhattacharya to a More Traditional Pick?
Trump, NIH, Jay Bhattacharya, Warp Speed, Leadership, Biomedical Research
Trump Nominates Surgeon Martin Makary for FDA Commissioner Amid Criticism of COVID Mandates
Trump, FDA, Martin Makary, COVID mandates, surgeon, nomination
Dr. Mehmet Oz Nominated to Lead Centers for Medicare and Medicaid Services
Dr. Mehmet Oz, Medicare, Medicaid, Centers for Medicare and Medicaid Services, Trump nomination, healthcare leadership
RFK Jr.’s HHS Nomination: A Potential Threat to the Biopharma Industry
RFK Jr., HHS nomination, biopharma industry, vaccine skepticism, health policies, Trump administration
Trump’s Return to the White House: Potential Implications for FDA and Biopharma M&A
Trump, FDA, Biopharma, M&A, Healthcare Policy, Robert F. Kennedy Jr.
Biopharma Industry Alarmed by Prospect of RFK Jr. Shaping FDA Policies Under Trump Administration
RFK Jr., FDA, Trump Administration, Biopharma, Healthcare Policy, Agriculture Policy